Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

Genetic testing may be the most effective way for researchers to distinguish between a rare form of kidney cancer and another that is more common, potentially preventing misdiagnoses, according to a recent study by researchers at Fox Chase Cancer Center and Temple University Hospital.

October 8, 2025
3 min

Fox Chase Cancer Center

1

Molecular testing is crucial for accurately diagnosing mucinous tubular and spindle cell carcinoma (MTSCC) and papillary renal cell carcinoma (PRCC).
2

MTSCC is a rare kidney cancer subtype characterized by tubules, spindle cells, and mucinous connective tissue.
3

Papillary formations, previously a marker for PRCC, were found in all five MTSCC cases studied, complicating diagnosis.
4

The research team compared MTSCC cases with papillary formation to PRCC cases and performed chromosomal analysis for confirmation.
5

Accurate diagnosis through molecular testing can lead to better treatment plans for patients with kidney cancer.

Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

1

2

3

4

5

Original Source(s)

Fox Chase Cancer Center and Temple Researchers Highlight Need for Molecular Testing in Diagnosing Two Types of Kidney Cancer

Related Content

Assessment of the effectiveness and safety of anti-VEGF/VEGFR monotherapy versus its combination with immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma: a network meta-analysis

Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy

Rethinking the evidence for intensive surveillance after renal tumor ablation